ACCESS (aleniglipron) Phase 2b obesity
Trial setup
- Program: ACCESS (Phase 2b) and exploratory ACCESS II (higher doses), randomized, double-blind, placebo-controlled. - Population: adults with obesity or overweight with comorbidity. - Duration: 36 weeks. - Key endpoints: mean percent change in body weight at Week 36 vs baseline; placebo-adjusted mean percent change; tolerability as discontinuation due to AEs.
Model leaderboard
How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better. Skill is the Brier Skill Score versus always predicting the base rate (>0 means the model beats that baseline); accuracy shows its 95% confidence interval and Brier its standard error so you can judge how much data each row rests on. Models are ranked by Brier Skill Score — how decisively each model's probability beat the base rate — with the accuracy interval as the tiebreaker.
No model results yet
This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.